OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-9.45%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$449M
AUM Growth
+$449M
(-21%)
Cap. Flow
-$41.6M
Cap. Flow
% of AUM
-9.26%
Top 10 Holdings %
Top 10 Hldgs %
73.91%
Holding
54
New
15
Increased
8
Reduced
14
Closed
9
Top Buys
| 1 |
SNWV
SANUWAVE Health, Inc. Common Stock
SNWV
|
$34.4M |
| 2 |
Immunome
IMNM
|
$10.2M |
| 3 |
Liquidia Corp
LQDA
|
$8.29M |
| 4 |
Anika Therapeutics
ANIK
|
$5.94M |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$4.82M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$68M |
| 2 |
Ocular Therapeutix
OCUL
|
$20.1M |
| 3 |
Trevi Therapeutics
TRVI
|
$9.58M |
| 4 |
Jasper Therapeutics
JSPR
|
$8.55M |
| 5 |
NewAmsterdam Pharma
NAMS
|
$8.35M |
Sector Composition
| 1 | Healthcare | 97.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $105M | 23.42% | 3,955,000 -35,000 | -0.9% | -$931K |
|
2
Eton Pharmaceutcials
ETON
$464M
| $37M | 8.24% | 2,852,070 | – | – |
|
|
SNWV
3
SANUWAVE Health, Inc. Common Stock
SNWV
$357M
| $34.4M | 7.65% | +972,002 | New | +$34.4M |
|
|
4
Liquidia Corp
LQDA
$2.38B
| $33.3M | 7.42% | 2,260,000 +561,858 | +33% | +$8.29M |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $26M | 5.78% | 490,000 -10,000 | -2% | -$530K |
|
6
Codexis
CDXS
$246M
| $25.6M | 5.69% | 9,500,000 +660,000 | +7% | +$1.78M |
|
|
7
Immunome
IMNM
$828M
| $23.9M | 5.32% | 3,550,000 +1,510,000 | +74% | +$10.2M |
|
|
8
TG Therapeutics
TGTX
$4.65B
| $21.1M | 4.7% | 535,000 -1,725,000 | -76% | -$68M |
|
9
Arvinas
ARVN
$568M
| $13.9M | 3.09% | 1,975,000 +350,000 | +22% | +$2.46M |
|
|
10
Ocular Therapeutix
OCUL
$2.12B
| $11.7M | 2.6% | 1,595,000 -2,747,500 | -63% | -$20.1M |
|
11
Edgewise Therapeutics
EWTX
$1.51B
| $8.69M | 1.93% | 395,000 -85,000 | -18% | -$1.87M |
|
12
Protara Therapeutics
TARA
$120M
| $7.37M | 1.64% | 1,730,000 -95,000 | -5% | -$405K |
|
13
Ginkgo Bioworks
DNA
$750M
| $6.81M | 1.52% | 1,195,000 -5,000 | -0.4% | -$28.5K |
|
|
14
Anika Therapeutics
ANIK
$135M
| $5.94M | 1.32% | +395,000 | New | +$5.94M |
|
15
Protagonist Therapeutics
PTGX
$3.67B
| $5.08M | 1.13% | 105,000 | – | – |
|
16
Xoma
XOMA
$392M
| $5.04M | 1.12% | 253,043 +3,043 | +1% | +$60.6K |
|
|
17
Trevi Therapeutics
TRVI
$883M
| $5M | 1.11% | 795,000 -1,522,500 | -66% | -$9.58M |
|
|
PVLA
18
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $4.82M | 1.07% | +172,357 | New | +$4.82M |
|
19
Gossamer Bio
GOSS
$562M
| $4.72M | 1.05% | 4,287,415 -202,585 | -5% | -$223K |
|
20
AnaptysBio
ANAB
$569M
| $4.66M | 1.04% | +250,933 | New | +$4.66M |
|
21
Disc Medicine
IRON
$2.07B
| $4.22M | 0.94% | +85,000 | New | +$4.22M |
|
22
Larimar Therapeutics
LRMR
$310M
| $4.12M | 0.92% | +1,914,077 | New | +$4.12M |
|
23
CG Oncology
CGON
$2.04B
| $4.02M | 0.89% | +163,988 | New | +$4.02M |
|
|
SLRN
24
DELISTED
ACELYRIN
SLRN
| $3.99M | 0.89% | 1,615,000 -620,000 | -28% | -$1.53M |
|
25
Avita Medical
RCEL
$117M
| $3.58M | 0.8% | +440,000 | New | +$3.58M |
|